Abstracts tagged "osteoporosis and quality of life"

Abstract Number: 1231 • 2013 ACR/ARHP Annual Meeting
The Quality Of Life and Resource Use Related To Hip Fractures Based On Data From The International Costs and Utilities Related To Osteoporotic Fractures Study
Moa Ivergård¹, Viktor Wintzell¹, László B Tankó², Victoria Barghout³, Axel Svedbom¹, Vidmantas Alekna⁴, Maria Luisa Bianchi⁵, Patricia Clark⁶, Manuel Díaz Curiel^7,8, Hans Peter Dimai⁹, Mikk Jürisson¹⁰, Olga Lesnyak¹¹, Eugene McCloskey¹², Kerrie M Sanders¹³, Thierry Thomas¹⁴, Fredrik Borgström¹⁵ and John A Kanis¹⁶, ¹OptumInsight, Stockholm, Sweden, ²Novartis Pharma AG, Basel, Switzerland, ³VEB HealthCare, Morristown, NJ, ⁴Vilnius University, Faculty of Medicine, Vilnius, Lithuania, ⁵Bone Metabolism Unit, Istituto Auxologico Italiano IRCCS, Milan, Italy, ⁶Clinical Epidemiology Unit, Hospital Infantil Federico Gómez and Faculty of Medicine UNAM, Mexico City, Mexico, ⁷Servicio de Medicina Interna/Enfermedades Metabolicas Osea, Fundacion Jimenez Diaz, Madrid, Spain, ⁸Catedra de Enfermedades Metabolicas Óseas, Universidad Autonoma, Madrid, Spain, ⁹Department of Internal Medicine, Division of Endocrinology and Metabolism, Medical University of Graz, Graz, Austria, ¹⁰Department of Public Health, Faculty of Medicine, Tartu University, Tartu, Estonia, ¹¹Ural State Medical Academy, Yekaterinburg, Russia, ¹²Academic Unit of Bone Metabolism, Metabolic Bone Centre, University of Sheffield, Sheffield, United Kingdom, ¹³Department of Medicine, NorthWest Academic Centre, The University of Melbourne, Melbourne, Australia, ¹⁴INSERM U1059, CHU-St-Etienne, Saint Etienne, France, ¹⁵LIME/MMC, Karolinska Institutet, Stockholm, Sweden, ¹⁶WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, Sheffield, United Kingdom
Background/Purpose: The International Costs and Utilities Related to Osteoporotic fractures Study (ICUROS) is an ongoing 18 months prospective observational study with the objective of estimating…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].